$DRIO

Matheis Dennis purchased $100K of DRIO

Matheis Dennis purchased 14,430 shares of DarioHealth Corp. (DRIO) at $6.93 on 2026-07-23.

Original reporting
SEC EDGAR · Matheis Dennis
Published Jul 28, 2026, 9:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DRIO
Bullish
medium confidence
Mentioned
$DRIO
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DRIOBullishLow
01

Why it matters

A director open-market purchase of about $100k is a small positive signal but does not change the company’s fundamentals based on the information provided.

02

Market read

Traders may note the insider buy for sentiment, but there is no new guidance, financial result, or operational milestone in the text.

03

What to watch

The article provides no context on prior insider activity, whether the director has a pattern of buys/sells, or any linkage to upcoming catalysts (earnings, trials, contracts).

Relevance 4/10Novelty 3/10Timing: after-hours/filing date, 2026-07-28, for a 2026-07-23 purchase

Background

The article is an SEC Form 4 insider transaction disclosure for DarioHealth Corp.

Company-level read

Ticker impact

$DRIOBullishMedium confidence
Context

SEC Form 4 shows director Matheis Dennis bought 14,430 shares of DarioHealth at $6.93 on 2026-07-23 for about $100k.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven and small.

Evidence & confidence

Form 4 insider purchases are primary-source but this transaction size is relatively small and provides no new operating or guidance information.

Market effects

No clear sector read-through; this is company-specific insider activity without new business metrics.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine or driven by liquidity/portfolio planning, and this one lacks a 10b5-1 plan or any accompanying fundamental disclosure.

Key entities

  • DarioHealth Corp.

    Subject of the Form 4 insider transaction disclosure.

  • Matheis Dennis

    Director who purchased 14,430 shares at $6.93 on 2026-07-23.

Related articles

$DRIOMedAI 8/10

Fortune 50 Employer Awards Dario Contract to Deliver AI

DarioHealth Corp. (NASDAQ: DRIO) said a Fortune 50 employer selected its AI-powered digital cardiometabolic care platform for diabetes and/or hypertension for over 100,000 eligible employees. The program is expected to launch in Fall 2026, with annual recurring revenue starting by year-end and increasing through 2027, according to the company.

$DRIOMed

Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth Strategy

DarioHealth Corp. (NASDAQ: DRIO) said a major U.S. health insurer extended and expanded its agreement, adding Dario’s hypertension solution after success with behavioral health. The insurer’s cardiometabolic rollout is expected to contribute revenue in 2026, with greater impact in 2027+. Dario said this is its third payer expansion beyond an initial condition.